Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Bioscns (NQ: APTO )

0.3850 -0.0050 (-1.28%)
Streaming Delayed Price Updated: 3:24 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Bioscns

< Previous 1 2 3 4 5 Next >
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences: Q3 Earnings Insights
Via Benzinga
Aptose Reports Results for the Third Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Expert Ratings for Aptose Biosciences
Via Benzinga
Analyst Expectations for Aptose Biosciences's Future
Via Benzinga
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
Company to Hold Clinical Update Webcast; Details Forthcoming 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know
Via Benzinga
Aptose Reports Results for the Second Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
From Aptose Biosciences, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Aptose Presents Highlights from Clinical Update
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Provides Update on Reverse Stock Split
Common Shares to begin trading on adjusted basis June 6 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
EHA Abstract on Tuspetinib and Venetoclax Recently Published 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Enters into $25 Million Committed Equity Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And... 
Via Benzinga
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
3 Stocks With 1,000% Upside Potential
If you're an investor comfortable with speculative bets, analysts are price targeting these stocks with 1000% upside. 
Via InvestorPlace
Aptose Reports Results for the First Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.